Evidence map›Paper›PMID 34179345›Full record

ReviewAdvanced therapeutics2021

Promising Immunotherapies against COVID-19.

Haodong Guo, Lili Zhou, Zhenyu Ma, Zhixin Tian, Fangfang Zhou

Open access · bronzeAbstract readReview
In one paragraph

Review in Advanced therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Haodong GuoJiangsu Key Laboratory of Infection and Immunity Institutes of Biology and Medical Sciences Soochow University Suzhou Jiangsu 215123 China.
Lili ZhouJiangsu Key Laboratory of Infection and Immunity Institutes of Biology and Medical Sciences Soochow University Suzhou Jiangsu 215123 China.
Zhenyu MaJiangsu Key Laboratory of Infection and Immunity Institutes of Biology and Medical Sciences Soochow University Suzhou Jiangsu 215123 China.
Zhixin TianJiangsu Key Laboratory of Infection and Immunity Institutes of Biology and Medical Sciences Soochow University Suzhou Jiangsu 215123 China.
Fangfang ZhouJiangsu Key Laboratory of Infection and Immunity Institutes of Biology and Medical Sciences Soochow University Suzhou Jiangsu 215123 China.ORCID https://orcid.org/0000-0003-1870-7584
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a severe pandemic and deeply affected the livelihood of people worldwide. In response to the pandemic, researchers have been rapidly studying different aspects of COVID-19, such as virus detection, vaccinations, and epidemiological aspects of the disease. It has been reported that SARS-CoV-2 can induce uncontrolled inflammation and cause a lack of antiviral response, thereby aggravating the disease. Therefore, recovery of immune functions is key to COVID-19 treatment. Many clinical trials are exploring suitable therapies, and some progress has been made. Early administration of interferons may prevent COVID-19 exacerbation and/or promotes recovery from the diseases. Inhibitors of inflammation can prevent cytokine storms and multi-organ damage. Convalescent plasma containing neutralizing antibodies has played an important role in therapeutic options at the beginning of the pandemic owing to the lack of other effective methods. To aid the development of treatment options for COVID-19, this review focuses on immunotherapies, including treatment with interferons, inhibition of pro-inflammatory mechanisms, and the use of convalescent plasma.

Indexed as

convalescent plasmacoronavirus disease 2019COVID‐19cytokine stormimmunotherapyinterferonsevere acute respiratory syndrome coronavirus 2

Identifiers

PMID34179345
PMCPMC8212093
OpenAlexW3161392388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.